Updated:
Alamar Biosciences
Alamar Biosciences, founded by Yuling Luo in 2018, has raised over $350M to commercialize attomolar-sensitivity proteomics for early disease detection.
Alamar Biosciences
Yuling Luo established Alamar Biosciences in 2018 in Fremont, California, building on decades of experience in ultrasensitive detection technologies. Before Alamar, Luo founded Advanced Cell Diagnostics, a spatial genomics pioneer acquired by Bio-Techne. Alamar's founding thesis addresses a persistent gap in proteomics: the inability to detect low-abundance proteins in blood at scale, limiting liquid-biopsy applications for cancer, neurology, and immunology. Alamar's core platform, the NULISA assay, achieves attomolar-range protein detection — roughly 1,000-fold more sensitive than conventional ELISA methods. The firm deploys capital into fully automated instrumentation, the ARGO HT system, which multiplexes thousands of protein measurements from microliter liquid samples. Confirmed partnerships include collaborations with the UK Biobank for large-scale population proteomics and multiple undisclosed pharmaceutical companies for companion diagnostics. In 2024, Alamar launched commercial assays for neurology, including phosphorylated tau and alpha-synuclein panels targeting Alzheimer's and Parkinson's disease research. The company operates out of its Fremont headquarters and distributes instruments directly to academic medical centers and biopharma R&D sites across North America, Europe, and Asia. Total disclosed financing exceeds $350 million, spanning a $128 million Series C in July 2023 and a $100 million Series C extension in February 2024. Investors include Sands Capital, Pavilion Capital, and Cowen Healthcare Investments. The team has grown to over 200 employees, with commercial operations accelerating after the ARGO system's formal launch. In March 2024: Alamar announced a strategic collaboration with Thermo Fisher Scientific to integrate NULISA assays onto Thermo Fisher's sample-handling workflow, significantly broadening the platform's accessibility to clinical labs (per BioPharma Dive, March 2024). Alamar operates a hybrid instrument-plus-consumables model — a structure that creates recurring revenue streams after instrument placement, differentiating it from pure sequencing-tool companies. The firm's intellectual property centers on a proximity-ligation chemistry that reduces cross-reactivity noise in multiplexed panels, addressing a primary failure mode in high-plex proteomics. While not a family office, Alamar's governance structure concentrates strategic control with founder Yuling Luo, who serves as Chairman and CEO, a posture reminiscent of long-horizon life-science platforms that prioritize technical milestones over near-term liquidity.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Fremont
Corporate office
Fremont, CA, United States
Principals
Yuling Luo
Founder, Chairman & CEO
Sector focus
Frequently asked questions
What technology underpins Alamar Biosciences' platform?
Alamar's core technology is the NULISA assay, an ultra-sensitive proximity-ligation immunoassay that achieves attomolar-level protein detection — approximately 1,000 times more sensitive than conventional ELISA tests. The chemistry reduces background noise through a proprietary sequential-binding and ligation design, enabling high-multiplex panels from tiny liquid-biopsy volumes. The platform is automated on the ARGO HT instrument.
How does Alamar Biosciences generate revenue?
Alamar follows an instrument-plus-consumables model. It sells the ARGO HT automated proteomics platform to academic medical centers and biopharma R&D labs, generating recurring revenue through proprietary NULISA assay kits and reagents. The company also pursues companion-diagnostics partnerships with pharmaceutical firms, where revenue includes milestone payments and royalties tied to clinical-use approvals.
Who are Alamar Biosciences' key competitors?
Alamar competes with established proteomics platforms including Olink (now part of Thermo Fisher), Quanterix, and SomaLogic (merged with Standard BioTools). Its specific advantage centers on combining ultra-high sensitivity with extensive multiplexing — a combination that Olink's PEA technology also targets, making Olink its closest comparable competitor.
Does Alamar Biosciences sell products directly or through partners?
Alamar sells its ARGO HT instruments and NULISA kits directly in North America. In 2024, it entered a strategic collaboration with Thermo Fisher Scientific, enabling integration of NULISA assays into Thermo Fisher's broader sample-handling and distribution ecosystem, which expands commercial reach to clinical laboratories globally.
What diseases does Alamar's platform target?
Alamar's initial commercial panels focus on neurology — including phosphorylated tau and alpha-synuclein biomarkers for Alzheimer's and Parkinson's disease — and oncology, detecting low-abundance circulating protein markers for early cancer detection. The platform is disease-agnostic, and the company is expanding into immunology and cardiovascular panels.
Who founded Alamar Biosciences and what is their background?
Yuling Luo, a serial entrepreneur in ultrasensitive molecular detection, founded Alamar in 2018. He previously founded Advanced Cell Diagnostics, which commercialized RNA in situ hybridization technology and was acquired by Bio-Techne. Luo's career has focused on spatial biology and enabling biomarker detection at previously inaccessible sensitivity levels.
Is Alamar Biosciences publicly traded?
No. Alamar Biosciences remains privately held as of mid-2025. The company raised a $128M Series C in 2023 and a $100M Series C extension in 2024, bringing total disclosed financing to over $350M. Key investors include Sands Capital, Pavilion Capital, and Cowen Healthcare Investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: